Most people notice a distinct pattern after receiving a gentamicin injection into the middle ear for Ménière’s disease: a few quiet days, then a stretch of off-balance feelings that peaks around one to two weeks before gradually fading. That disequilibrium phase, which can feel alarming, is actually a sign the drug is doing its job. Beyond the immediate recovery, the treatment controls vertigo attacks in a large majority of patients, though the trade-offs involving hearing, balance, and the possibility of repeat injections are worth understanding before you go in.
What Happens in the First Week
The injection itself is done in a clinic. Your doctor numbs the eardrum with a local anesthetic, then passes a thin needle through it to deposit gentamicin solution into the middle ear space. You lie on your side with the treated ear facing up for roughly 20 to 30 minutes so the medication can soak through the round window membrane into the inner ear. The drug diffuses through that membrane and reaches the fluid-filled spaces of the inner ear, where concentrations can vary considerably from person to person.
For the first day or two, most people feel relatively normal apart from some ear fullness and mild soreness at the injection site. Some describe a brief spell of dizziness right after the procedure, but it tends to pass quickly. You’ll be told to avoid getting water in the ear until the tiny eardrum puncture heals, which usually takes a few days. Blowing your nose forcefully and heavy lifting are also discouraged for a short period.
Around days three to five, the gentamicin starts affecting the vestibular hair cells in the inner ear. This is when you may begin to feel a new kind of imbalance, different from the spinning vertigo of a Ménière’s attack. It is more of a wobbly, unsteady sensation, as if the floor is slightly unreliable underfoot. This disequilibrium tends to intensify over the next week or so, typically peaking around 10 to 14 days after injection.1Operative Techniques in Otolaryngology-Head and Neck Surgery. Intratympanic gentamicin injection for Meniere’s disease
Why Feeling Off-Balance Is Actually a Good Sign
Gentamicin is an antibiotic, but when placed directly in the ear, its purpose is not to fight infection. It selectively damages the vestibular hair cells that send faulty signals causing your vertigo attacks. Research on inner-ear tissue after treatment shows that type I vestibular hair cells, one of the two main types that detect head movement, absorb far more gentamicin than type II cells.2PubMed Central. Gentamicin is primarily localized in vestibular type I hair cells after intratympanic administration This preferential damage to the balance sensors, while sparing hearing structures to a greater degree, is what makes the treatment useful. Gentamicin is more toxic to the balance organ than to the hearing organ, though it is not perfectly selective.
The temporary increase in unsteadiness reflects the vestibular system on the treated side losing function. Studies tracking postural sway after treatment found that body sway speeds roughly doubled two weeks after injection, confirming that your balance system is going through a significant shift during that window.3Journal of Vestibular Research. Postural compensation after intratympanic gentamicin treatment of Meniere’s disease If you experience that wobbly phase, it generally means the gentamicin has reached its target. Patients who feel essentially nothing after the injection sometimes need a repeat dose because the drug did not penetrate sufficiently.
The Weeks and Months After
After the peak around two weeks, the unsteadiness gradually improves as your brain adapts to relying more on the untreated ear and on visual and body-position cues. Most people find the worst of the imbalance resolves over several weeks, though subtle balance issues can persist longer, especially in dark environments or on uneven surfaces where your brain cannot lean on visual input as easily.
Roughly 20 to 50 percent of treated patients report some degree of lingering unsteadiness that affects daily activities, emotional well-being, or both.4PubMed Central. Effect of vestibular rehabilitation treatment (VRT) on patients with unsteadiness after intratympanic gentamicin in Menière’s disease: protocol for a randomised controlled trial That is a wide range because people’s compensation ability varies a lot, depending on age, activity level, and whether the opposite ear is healthy. Younger, more active patients tend to compensate faster.
Vestibular rehabilitation, a guided exercise program that challenges your balance system to retrain itself, is commonly recommended if unsteadiness lingers. The exercises typically involve head movements, gaze stabilization drills, and balance tasks that gradually increase in difficulty. There is enough concern about persistent unsteadiness that researchers are currently running randomized trials specifically to test how much formal rehab helps this patient group.4PubMed Central. Effect of vestibular rehabilitation treatment (VRT) on patients with unsteadiness after intratympanic gentamicin in Menière’s disease: protocol for a randomised controlled trial In the meantime, most ear specialists will still refer you for it because the logic is sound and anecdotal outcomes are encouraging.
How Effectively Does It Stop Vertigo Attacks?
This is the number most people want, and the evidence is consistently encouraging. Across multiple studies, gentamicin injections control vertigo in roughly 80 to 96 percent of patients, depending on how “control” is defined and how long patients are followed.1Operative Techniques in Otolaryngology-Head and Neck Surgery. Intratympanic gentamicin injection for Meniere’s disease Some studies define success as complete elimination of vertigo episodes, while others include patients whose attacks become substantially less frequent and less intense.
In one study following patients over the long term, about 58 percent achieved full remission from vertigo and another 38 percent had substantial control, meaning attacks occurred but were milder. Combined, that put effective vertigo control at about 96 percent.5PubMed Central. One-shot, low-dosage intratympanic gentamicin for Ménière’s disease: Clinical, posturographic and vestibular test findings A separate long-term study of 78 patients found that treatment was effective enough to avoid more aggressive surgery in 96 percent of cases.6PubMed Central. Time Course of Repeated Intratympanic Gentamicin for Ménière’s Disease Not every study hits those numbers. One using a low-dose protocol reported complete vertigo control in about 53 percent and effective control in about 59 percent, with hearing preserved in nearly all patients.7PubMed Central. Low Dose Intratympanic Gentamicin in Ménière’s Disease The variation largely comes down to dosing strategy, how many injections were given, and how strictly vertigo control was measured.
Beyond vertigo, about three-quarters of patients in one study reported improvement in aural fullness and tinnitus, two other hallmarks of Ménière’s disease.5PubMed Central. One-shot, low-dosage intratympanic gentamicin for Ménière’s disease: Clinical, posturographic and vestibular test findings These secondary benefits are not guaranteed, but they are a welcome bonus when they happen.
What About Your Hearing?
Hearing loss is the most-discussed risk, and the one that weighs most heavily on people considering the procedure. Gentamicin is more damaging to balance cells than hearing cells, but it is not completely safe for hearing. The risk depends substantially on dose and protocol.
In a long-term hearing study of 34 patients, hearing stayed the same in about 68 percent, actually improved in 15 percent, and worsened in 17 percent. Profound hearing loss, meaning the ear became essentially non-functional for hearing, occurred in one patient out of 34, roughly 3 percent.8PubMed. Long-term hearing outcome in patients receiving intratympanic gentamicin for Ménière’s disease High-dose regimens carry more hearing risk than the low-dose, titration-based protocols that most clinics now favor.1Operative Techniques in Otolaryngology-Head and Neck Surgery. Intratympanic gentamicin injection for Meniere’s disease
It is also worth keeping in mind that Ménière’s disease itself causes progressive hearing loss over time. Some of the hearing decline people notice after treatment may have happened anyway as part of the disease’s natural course. Your doctor will likely do hearing tests before and after the injection to track any changes and distinguish treatment effects from disease progression.
Will You Need More Than One Injection?
Many protocols start with a single injection, then wait and see. If vertigo attacks return or never fully stop, a second injection can be given. In one study, about 53 percent of patients needed only one dose, while the remaining 47 percent received a second.7PubMed Central. Low Dose Intratympanic Gentamicin in Ménière’s Disease When a second injection was needed, it came on average about eight months after the first.9PubMed Central. Low-Dose Intratympanic Gentamicin Injections for Intractable Meniere’s Disease: How Many Are Optimal?
The “titration” approach, giving the minimum dose needed and waiting for a clinical response before considering more, has become the standard precisely because it balances vertigo control against hearing risk. Research suggests that a second low-dose injection in patients who respond poorly or relapse is reasonable, but going much beyond two starts to raise questions about diminishing returns and increasing hearing risk.9PubMed Central. Low-Dose Intratympanic Gentamicin Injections for Intractable Meniere’s Disease: How Many Are Optimal?
Vestibular Function Recovery
An interesting wrinkle is that the vestibular damage from gentamicin is not always permanent. Roughly one-third of patients who initially lose measurable vestibular function on the treated side show signs of recovery on balance tests within about two years.10PubMed. Intratympanic gentamicin injections for Meniere disease: vestibular hair cell impairment and regeneration Whether this represents partial hair cell regeneration or the brain simply routing around the damage is still debated. For some patients, this vestibular recovery is welcome because it means better long-term balance. For others, it may be part of why vertigo eventually returns and a repeat injection becomes necessary. It is a double-edged finding: your balance system’s resilience can work in your favor for daily functioning, but it can also reopen the door to recurrent attacks.
Quality of Life Changes
Numbers on vertigo control and hearing are important, but what most people really want to know is whether their life will actually feel better. Studies using standardized quality-of-life questionnaires suggest it does. One assessment using the Glasgow Benefit Inventory, which measures perceived health benefit across general, physical, and social dimensions, found a total benefit score of about +30 on a scale where zero means no change and positive scores mean improvement. General health benefit scored highest, followed by physical health and then social functioning.11PubMed. Intratympanic gentamicin for Ménière’s disease: effect on quality of life as assessed by Glasgow benefit inventory
That finding aligns with what patients commonly describe: the relief of not living in fear of the next vertigo attack, which can strike without warning, last hours, and leave you incapacitated, is transformative even if you trade it for some unsteadiness or mild hearing changes. The psychological burden of unpredictable vertigo is something that does not always show up in clinical outcome tables but dominates the patient experience. Removing that unpredictability is often worth the trade-offs, which is why gentamicin injection is considered a frontline option when medications and dietary changes stop working.
How It Stacks Up Against Other Treatments
Gentamicin is not the only option for Ménière’s disease that has failed to respond to conservative management. The two main alternatives are intratympanic steroid injections and surgery.
A head-to-head trial comparing gentamicin to intratympanic methylprednisolone, a steroid, found that steroid injections were also effective at controlling vertigo. The researchers concluded that the steroid is a viable non-ablative option, meaning it does not intentionally destroy vestibular tissue, and that the choice between the two should be made based on the individual patient’s circumstances.12The Lancet. Intratympanic methylprednisolone versus gentamicin in patients with unilateral Ménière’s disease: a randomised, double-blind, comparative effectiveness trial Steroids carry less hearing risk, which makes them attractive, but some clinicians feel gentamicin offers more durable vertigo relief in severe cases. The evidence does not decisively favor one over the other for every patient.
On the surgical side, endolymphatic sac surgery is a less destructive surgical option sometimes tried before gentamicin. A retrospective comparison found that vertigo control rates were similar between the two treatments, but patients who had gentamicin injection needed fewer secondary procedures, had more stable hearing afterward, and reported better functional levels and quality of life.13PubMed Central. Endolymphatic sac surgery versus intratympanic gentamicin for the treatment of intractable Ménière’s disease: a retrospective review with survey More aggressive surgery, like vestibular nerve section or labyrinthectomy, is generally reserved for cases where gentamicin and other less invasive approaches have failed. Those procedures are highly effective at stopping vertigo but carry greater surgical risk and cause complete vestibular loss on that side.
Oscillopsia and Other Uncommon Side Effects
Most discussion of side effects focuses on hearing loss and unsteadiness, but there is a less common symptom worth mentioning: oscillopsia, the sensation that the visual world bounces or jiggles with each step you take. This happens when vestibular damage is severe enough that the reflexes stabilizing your gaze during head movement stop working properly. A case series of patients with severe labyrinthine damage from gentamicin found that they consistently described a vertical bouncing of their surroundings when walking, timed to each footfall.14PubMed. Bobbing oscillopsia from gentamicin toxicity That series involved systemic (intravenous) gentamicin rather than the targeted ear injections used for Ménière’s, so the risk is much lower with intratympanic delivery. Still, if you notice that the world seems to bounce when you walk after treatment, it is a recognized effect and worth reporting to your doctor.
Another concern that comes up in bilateral Ménière’s disease is the possibility of damaging both vestibular systems. Since about 15 to 40 percent of Ménière’s patients eventually develop symptoms in the second ear, treating one side with gentamicin carries a theoretical risk of leaving someone with reduced vestibular function on both sides if the untreated ear later becomes affected. This is one reason clinicians are cautious about treating bilateral disease with gentamicin and may lean toward steroid injections or surgery in patients who show signs of involvement in both ears.
What Varies Between Patients
One of the frustrating things about gentamicin injection is how unpredictable individual responses can be. Even when the same dose and protocol are used, the amount of drug that actually reaches the inner ear varies widely. Measurements of gentamicin concentration in inner-ear fluid after injection showed a range from essentially zero to 16 mg/L across patients, which is a huge spread.15PubMed. Round window gentamicin absorption: an in vivo human model Differences in round window membrane thickness, the presence of scar tissue or mucus over the membrane, and how long the patient stays positioned with the treated ear up all affect absorption.
This variability explains why some people feel strong effects from one injection while others need two or more, and why hearing risk is hard to predict on an individual level. It also explains why protocols have shifted toward starting low and adding more only if needed, rather than giving large doses upfront. Your doctor cannot know in advance exactly how much gentamicin your ear will absorb, so the conservative approach is to give a modest amount and let your clinical response guide next steps.